The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs.

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143-1695, USA.
Hematology/Oncology Clinics of North America (Impact Factor: 2.07). 09/2006; 20(4):797-809. DOI: 10.1016/j.hoc.2006.03.002
Source: PubMed

ABSTRACT Aspirin and other NSAIDs have a potential role in the primary and secondary prevention of many common diseases associated with aging, including the top two causes of mortality in the United States-cardiovascular disease and cancer. These agents may be beneficial in the management of Alzheimer's disease,other forms of dementia, and Parkinson's. disease. Because men with prostate cancer or precancer are likely to present with coexisting conditions that would be affected by systemic aspirin, NSAID, or other COX-2 inhibitor therapies, it is important to consider any possible preventive studies or future clinical recommendations of aspirin or NSAIDs for prostate cancer within the context of these comorbid conditions. Aspirin or nonaspirin NSAIDs may be appropriate prevention therapy for patients at high risk of prostate cancer, myocardial infarction, Parkinson's disease, Alzheimer's disease, lung cancer, or colorectal cancer, but low risk for gastrointestinal complications or stroke. Further quantitative comparative studies of the risks and benefits of these common comorbidities in older Americans, with special attention to dose and duration parameters, are warranted.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Polyunsaturated fatty acids (PUFA) play important roles in the normal physiology and in pathological states including inflammation and cancer. While much is known about the biosynthesis and biological activities of eicosanoids derived from ω6 PUFA, our understanding of the corresponding ω3 series lipid mediators is still rudimentary. The purpose of this review is not to offer a comprehensive summary of the literature on fatty acids in prostate cancer but rather to highlight some of the areas where key questions remain to be addressed. These include substrate preference and polymorphic variants of enzymes involved in the metabolism of PUFA, the relationship between de novo lipid synthesis and dietary lipid metabolism pathways, the contribution of cyclooxygenases and lipoxygenases as well as terminal synthases and prostanoid receptors in prostate cancer, and the potential role of PUFA in angiogenesis and cell surface receptor signaling.
    CANCER AND METASTASIS REVIEW 12/2011; 30(3-4):295-309. · 9.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several reports have shown that the incidence of prostate cancer is on the increase and that more men would be diagnosed of prostate cancer in the next decades. Many approaches are being applied towards reducing the cases of prostate cancer, especially in the very rich countries. However, these have not been effective due to the poor current understanding of the pathophysiology of prostate carcinogenesis. The current work presents a review of how chronic infection and inflammation may contribute to prostate carcinogenesis.
    Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases 03/2011; 11(6):1195-8. · 3.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The high global incidence of prostate cancer has led to a focus on chemoprevention strategies to reduce the public health impact of the disease. Early studies indicating that selenium and vitamin E might protect against prostate cancer encouraged large-scale studies that produced mixed clinical results. Next-generation prostate cancer prevention trials validated the impact of 5α-reductase inhibitors in hormone-responsive prostate cancer, and these results were confirmed in follow-up studies. Other interventions on the horizon, involving both dietary and pharmacological agents, hold some promise but require further investigation to validate their efficacy. In this Review, we discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention.
    Nature Reviews Clinical Oncology 11/2013; · 15.03 Impact Factor